DRD3

D(3) dopamine receptor · P35462 · DRD3 on Sugi Atlas →

668,774 patent compounds predicted against DRD3, 420,244 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL8511	1.00	8/20
Mianserin (SCHEMBL18020)	1.00	8/20
SCHEMBL8078	0.85	8/20
Ketotifen (SCHEMBL4436)	1.00	7/20
Ketotifen (SCHEMBL8809)	1.00	7/20
Ketotifen (SCHEMBL8810)	1.00	7/20
Prochlorperazine (SCHEMBL18429)	1.00	7/20
SCHEMBL7929	0.79	7/20
Antrafenine (SCHEMBL24297)	0.49	7/20
Hydroxyzine (SCHEMBL4491)	1.00	6/20
Hydroxyzine (SCHEMBL4492)	1.00	6/20
Promethazine (SCHEMBL4700)	1.00	6/20
Amitriptyline (SCHEMBL7824)	1.00	6/20
Methylpromazine (SCHEMBL18993)	1.00	6/20
Methylpromazine (SCHEMBL18994)	1.00	6/20
Levomepromazine (SCHEMBL25462)	1.00	6/20
Clebopride (SCHEMBL25710)	1.00	6/20
Aminopromazine (SCHEMBL25156)	0.70	6/20
Ergotamine (SCHEMBL1483)	1.00	5/20
Cetirizine (SCHEMBL4176)	1.00	5/20

Clinical trials — most relevant to DRD3 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Adjunct Treatment With Cariprazine for Adults With Attention-deficit/Hyperactivity Disorder	PHASE4	UNKNOWN
Identify Peripheral Biomarkers of Symptomatology, Neurocognitive Functions, and Medication Response in ADHD	PHASE4	UNKNOWN
Dopamine Enhancement of Fear Extinction Learning in PTSD (1R21MH108753)	PHASE4	COMPLETED
Effects of Rasagiline on Sleep Disturbances in Parkinson's Disease	PHASE4	COMPLETED
Disturbance of Plasma Cytokine Parameters in Clozapine-Resistant Treatment-Refractory Schizophrenia (CTRS) and Their Association With Combination Therapy	PHASE4	COMPLETED
A New Pharmacotherapy for Alcohol Dependence: Olanzapine	PHASE3	COMPLETED
Examination of Bromocriptine on Homeostatic and Hedonic Mechanisms of Food Intake in Individuals at High Risk for T2DM	PHASE3	COMPLETED
New Treatment for Alcohol and Nicotine Dependence	PHASE2/PHASE3	COMPLETED
Psychopharmacology for Cocaine Dependence - Buspirone	PHASE2	COMPLETED
Exploring Occupancy of Dopamine D3 Receptor by Buspirone in Humans Using PET	PHASE1/PHASE2	COMPLETED
Buspirone, Stress, and Attentional Bias to Marijuana Cues	PHASE2	COMPLETED
D1 and D2 Dopamine Receptors in Gambling and Amphetamine Reinforcement	PHASE2	COMPLETED
Vitamin D in OUD: Exploration of Alterations on the Dopamine D2/D3 Receptor System	PHASE1	COMPLETED
Positron Emission Tomography Imaging of Dopamine Receptors Using the Tracer [11C]NNC-112	PHASE1	COMPLETED
Brain Dopaminergic Signaling in Opioid Use Disorders	EARLY_PHASE1	COMPLETED
A Study on Risk Mutations of Vulnerability Genes of Schizophrenia	nan	UNKNOWN
Functional Relevance of Dopamine Receptors in Healthy Controls and Patients With Schizophrenia: Characterization Through [11C]NNC-112 and [18F]Fallypride Positron Emission Tomography	nan	COMPLETED
A Combined Psycho-pharmacological and Brain Imaging Study of Human Sexuality	nan	SUSPENDED
A Positional Cloning Study on Schizophrenia	nan	COMPLETED
Exploring Regulation and Function of Dopamine D3 Receptors in Alcohol Use Disorders: A [11C]-(+)-PHNO Study	nan	COMPLETED
A Brain Imaging Study Into Nicotine Induced Dopamine Release in Cigarette Smokers.	nan	UNKNOWN
Molecular Genetic Study of Schizophrenia: Parent-Offspring Trios	nan	COMPLETED
Neuroimaging of Dopamine Metabolism in Normal and Psychiatric Patients	nan	COMPLETED
Dopamine Receptor Imaging in Mood Disorders	nan	COMPLETED
Dopamine and Insulin Resistance	nan	COMPLETED
Adjuvant Therapy With Pergolide in Treating Cognitive Deficits in Schizophrenia	nan	COMPLETED
Dopamine Effect on Inhibitory Control	nan	COMPLETED
Dopamine D2 and D3 Receptor Occupancy and Clinical Response in Older Patients With Schizophrenia	nan	UNKNOWN
Nicotine Reinforcement and Smoking-Cue Reactivity: Association With Genetic Polymorphisms	nan	COMPLETED
The Genetic Basis for Vulnerability to Substance Abuse	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a DRD3 binder may also engage these)

Protein	Name	Similarity
Q5IS72	—	1.000	Q5IS72 →
P52703	—	1.000	P52703 →
P19020	—	1.000	P19020 →
Q91175	—	0.999	Q91175 →
P54833	—	0.997	P54833 →
P30728	—	0.997	P30728 →
P18901	—	0.996	P18901 →
HTR1B	5-hydroxytryptamine receptor 1B	0.996	landscape →
Q6XXX9	—	0.996	Q6XXX9 →
Q28997	—	0.996	Q28997 →
O70528	—	0.995	O70528 →
P79748	—	0.994	P79748 →
O42384	—	0.994	O42384 →
Q6XXY0	—	0.994	Q6XXY0 →
Q4KWL2	—	0.993	Q4KWL2 →
Q9N2B7	—	0.993	Q9N2B7 →
P04274	—	0.993	P04274 →
P10608	—	0.993	P10608 →
DRD1	D(1A) dopamine receptor	0.993	landscape →
P50130	—	0.992	P50130 →
DRD2	D(2) dopamine receptor	0.992	landscape →
HTR4	5-hydroxytryptamine receptor 4	0.992	landscape →
Q0EAB5	—	0.992	Q0EAB5 →
P42288	—	0.992	P42288 →
P30966	—	0.992	P30966 →
P35404	—	0.992	P35404 →
Q95136	—	0.992	Q95136 →
P47800	—	0.992	P47800 →
Q6XXX8	—	0.992	Q6XXX8 →
P79250	—	0.992	P79250 →